Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?

Kastrup, Jens

doi:10.1016/j.imbio.2011.04.007

Cited by 88 publications

(79 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have reported that circulating YKL-40 level is elevated in patients with diabetes and obesity (7)(8)(9)(10). The entire population in the present study has high body mass index, and the prevalence of diabetes in patients with CAE and CAD tends to be higher than in those with NCA, although there is no significant difference between the groups.…”

contrasting

confidence: 46%

Could YKL-40 be used as a new marker for coronary artery ectasia?

Kim¹

2013

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

contrasting

confidence: 46%

Could YKL-40 be used as a new marker for coronary artery ectasia?

Kim¹

2013

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

“…In contrast, no such differences were noted in another study 16) . Meanwhile, Sharma et al suggested that the endothelial function is disrupted in pediatric NS 22,23) , and it has been documented that the YKL-40 levels are elevated in patients with inflammatory diseases 24) . The participation of YKL-40 in the pathogenesis of vascular incidents and inflammation suggests that this marker may have a role in the development of endothelial dysfunction and atherosclerosis.…”

Section: Discussionmentioning

confidence: 99%

The Serum YKL-40 Level is Associated with Vascular Injury and Predicts Proteinuria in Nephrotic Syndrome Patients

Koçyiğit

Güngör

Doğan

et al. 2015

JAT

View full text Add to dashboard Cite

Aim: Nephrotic syndrome (NS) is associated with an increased rate of cardiovascular events. The YKL-40 level is associated with atherosclerosis, endothelial dysfunction and proteinuria in renal and non-renal populations. The aim of this study was to investigate the relationships between the YKL-40 level and both vascular injury and proteinuria in NS patients. Methods: Sixty-nine NS patients and 20 healthy subjects were enrolled in the present study. The endothelial function was assessed according to the flow mediated dilatation (FMD) and the degree of arterial stiffness was determined based on the pulse wave velocity (PWV). The serum YKL-40 levels were measured using ELISA. Results: The YKL-40 levels and PWV values were higher and the FMD values were lower in the NS patients than in the healthy controls. However, the CA-IMT and LVEF levels were not statistically different between the two groups. The patients were divided into three groups with respect to the extent of proteinuria: the normoproteinuria group (n:18), non-nephrotic proteinuria group (n:33) and nephrotic proteinuria group (n:18). Consequently, the YKL-40 levels and PWV values were significantly increased and the FMD values were decreased in the nephrotic proteinuria group compared to that observed in both the non-nephrotic proteinuria and normoproteinuria groups.

show abstract

“…Whether this indicates that these controls indeed had an ongoing subclinical inflammatory process is possible and raises the possibility that PTX3 might be a potential future risk biomarker in diseases characterized by subclinical inflammation as cardiovascular diseases even in individuals with no apparent symptoms in line with what has been suggested for CRP, suPAR and YKL-40 [23][24][25].…”

Section: Ptx3 Versus Crpmentioning

confidence: 96%

Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome

Bastrup-Birk

Skjoedt

Munthe-Fog

et al. 2013

Molecular Immunology

View full text Add to dashboard Cite

The long pentraxin-3 (PTX3) is a key component of the humoral arm of the innate immune system. PTX3 is produced locally in response to pro-inflammatory stimuli. To investigate PTX3 levels and its use as a biomarker in patients with systemic inflammation, we developed a solid-phase enzyme-linked immunosorbent assay based on novel anti-PTX3 monoclonal antibodies detecting PTX3 with high sensitivity. The assay was applied on 261 consecutive patients admitted to an intensive care unit prospectively monitored with the systemic inflammatory response syndrome (SIRS). 100 blood donors were included as controls. PTX3 levels were elevated in patients (median = 71.3 ng/ml) compared with the controls (median = 0 ng/ml) (Mann-Whitney, p,0.0001). ROC analysis showed that PTX3 levels were significantly specific (85.0%) and sensitive (89.1%) to discriminate between healthy controls and patients (area under the curve (AUC) 0.922 (95% CI 0.892 to 0.946, p,0.0001)). Higher levels of PTX3 were associated with the development of sepsis, severe sepsis and septic shock (p = 0.0001). The serum levels of PTX3 correlated significantly with SAPS2 score (Spearman's rho 0.28, p,0.0001). Patients with high levels of PTX3 at admission did have a higher 90 day mortality rate than patients with the 25% lowest levels (Cox regression analysis, hazard ratio 3.0, p = 0.0009). In conclusion, we have established a highly sensitive and robust assay for measurement of PTX3 and found that its serum concentrations correlated with disease severity and mortality in patients with SIRS and sepsis.

show abstract

Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?

Cited by 88 publications

References 111 publications

Could YKL-40 be used as a new marker for coronary artery ectasia?

Could YKL-40 be used as a new marker for coronary artery ectasia?

The Serum YKL-40 Level is Associated with Vascular Injury and Predicts Proteinuria in Nephrotic Syndrome Patients

Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome

Contact Info

Product

Resources

About